Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +50.33%
#3 Black Phoenix Black Phoenix +34.86%
#4 Velvet Velvet +32.55%
#5 Akedo Akedo +22.72%
#6 Fake World Assets Fake World Assets +19.66%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.95%
#8 DoubleZero DoubleZero +16.74%
#9 Palladium Network Palladium Network +15.82%
#10 clBTC clBTC +11.69%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFI
Classifica tra le azioni #40134
Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge,... Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
Prezzo delle azioni
$0.0039
Ultima sincronizzazione: 2023-10-27
Capitalizzazione di mercato
$235.97K
Variazione (1 giorno)
-13.33%
Variazione (1 anno)
0.00%
Paese
US
Scambia Infinity Pharmaceuticals, Inc. (INFI)

Categoria

Healthcare
Utile per Infinity Pharmaceuticals, Inc. (INFI)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Infinity Pharmaceuticals, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Infinity Pharmaceuticals, Inc. dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE